We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.00
Bid: 4.75
Ask: 5.25
Change: -0.375 (-6.98%)
Spread: 0.50 (10.526%)
Open: 5.375
High: 5.375
Low: 5.00
Prev. Close: 5.375
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

5 Feb 2020 17:38

RNS Number : 1217C
Genedrive PLC
05 February 2020
 

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Lisa Miele, a Person Closely Associated with Gino Miele R&D Director and a PDMR, acquired 8,636 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 8.875p per today.

 

Following these purchases, Gino Miele's total beneficial interest is 66,979 Ordinary Shares, 0.2% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Lisa Miele

 

 

2.

Reason for the notification

a.

Position/status

PCA of Gino Miele R&D Director

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

 

 

 

GB00B1VKB244

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

8.875p

8,636

 

d.

Aggregated information

·; Aggregated volume

·; Price

 

 

N/A

 

e.

Date of the transaction

2020-02-05

f.

Place of the transaction

London Stock Exchange, AIM

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

Stanford Capital Partners Limited (Joint Broker)

+44 (0)20 3815 8880

Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAXASEDDEEFA
Date   Source Headline
3rd Dec 20197:00 amRNSAIHL assay kit demonstrates high clinical accuracy
27th Nov 20194:23 pmRNSResult of AGM
22nd Nov 20192:41 pmRNSDirector/PDMR Shareholding
21st Nov 201912:30 pmEQSHardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
18th Nov 20197:00 amRNSAntibiotic Induced Hearing Loss Assay CE marking
6th Nov 20197:00 amRNSNotice of AGM and Change of Auditors
28th Oct 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
22nd Oct 20193:07 pmRNSHolding(s) in Company
22nd Oct 20193:06 pmRNSHolding(s) in Company
7th Oct 20197:00 amRNSNHS Ethics approval for use of AIHL test in trials
3rd Oct 20197:00 amRNSFinal Results
9th Sep 20197:00 amRNSNotice of Results
18th Jul 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations
18th Jul 20197:00 amRNSDirector/PDMR Shareholding
9th Jul 20197:00 amRNSTrading Update
8th Apr 201910:54 amEQSHardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats
5th Apr 20198:29 amRNSDirector/PDMR Shareholding
28th Mar 20197:00 amRNSHalf-year Report
16th Jan 20191:21 pmRNSHolding(s) in Company
15th Jan 20197:00 amRNSTrading update
31st Dec 201811:30 amRNSResult of AGM
12th Dec 20187:49 amRNSHolding(s) in Company
11th Dec 20187:15 amEQSHardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales
10th Dec 20184:44 pmRNSHolding(s) in Company
10th Dec 20183:40 pmRNSHolding(s) in Company
10th Dec 201811:04 amRNSHolding(s) in Company
7th Dec 20183:07 pmRNS2018 Annual Report and AGM Notice
7th Dec 20182:59 pmRNSResult of GM
29th Nov 20187:00 amRNSAbbVie to use HCV assay in study
19th Nov 20183:27 pmRNSPosting of Shareholder Circular
16th Nov 20181:42 pmRNSResult of Equity Placing
16th Nov 20187:00 amRNSProposed Placing and Broker Option
16th Nov 20187:00 amRNSUnaudited Preliminary Results
10th Sep 20181:46 pmRNSDirector/PDMR Shareholding
24th Aug 20187:00 amRNSNotice of GM
22nd Aug 20187:00 amRNSBoard Appointment
8th Aug 20187:00 amRNSgenedrive partners with FIND to evaluate HCV test
19th Jul 20187:00 amRNSDirector/PDMR Shareholding
13th Jul 20187:00 amRNSTrading Update
29th Jun 20189:36 amRNSTotal Voting Rights
27th Jun 20187:15 amEQSHardman & Co Research: genedrive plc (GDR): Preventing hearing loss in newborns
20th Jun 20187:00 amRNSGrant for NHS point-of-care test
19th Jun 201811:18 amRNSAdditional Listing of Shares
11th Jun 20189:25 amRNSCompletion of Disposal
4th Jun 20184:47 pmRNSResult of General Meeting
17th May 20182:32 pmRNSCircular re Proposed Disposal
14th May 20185:39 pmRNSProposed disposal for up to £1.9 million in cash
10th May 201811:39 amRNSHolding(s) in Company
18th Apr 20187:00 amRNSgenedrive plc to Present at the UK Investor Show
12th Apr 20189:53 amEQSHardman & Co Research: genedrive plc (GDR): Progressing commercialisation plans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.